Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies

(Oct 22, 2025) by Darren Incorvaia.

Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion.

The New York-based biopharma will provide binders that ModeX will pair with its platform to fashion new multispecific antibodies for a range of disease areas, including immunology, oncology and metabolic diseases, according to an Oct. 29 release.

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone payments that could top $200 million for each chosen antibody.